Abstracts tagged "lymphocytes and rheumatoid arthritis (RA)"

Abstract Number: 88 • 2018 ACR/ARHP Annual Meeting
Lymphocyte DNA Methylation As a Mediator of Genetic Risk in Rheumatoid Arthritis
Alex Clark^1,2, Nisha Nair³, Andrew Skelton^1,2, Amy Anderson^1,2, Nishanthi Thalayasingam^1,2, Najib Naamane^1,2, Julie Diboll^1,2, Jonathan Massey⁴, Stephen Eyre^3,4, Anne Barton^3,4, John Isaacs^1,2, Louise Reynard⁵ and Arthur Pratt^1,2, ¹Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ²NIHR, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ³Arthritis Research UK Centre for Genetics and Genomics and Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, ⁴NIHR Manchester Musculoskeletal Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom, ⁵Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom
Background/Purpose: Genome-wide association studies (GWAS) have to date identified over 100 genomic loci at which single nucleotide polymorphisms (SNPs) confer an increased risk of developing…
Abstract Number: 618 • 2018 ACR/ARHP Annual Meeting
Blood Lymphocytes Subtypes As Biomarkers for Early Identification of Optimal Responders to Anti-TNF Treatment in Rheumatoid Arthritis
Cristina Sobrino¹, Borja Hernández-Breijo², Israel Gañán-Nieto¹, Carlota García-Hoz¹, Victoria Navarro-Compán², Ana Martínez², Javier Bachiller¹, María Gema Bonilla Hernán², Dora Pascual-Salcedo², Garbiñe Roy¹, Mónica Vázquez¹, Alejandro Balsa², Luisa María Villar¹, Chamaida Plasencia² and Eulalia Rodríguez-Martín¹, ¹Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ²Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are the most common biologicalagents used as disease-modifying treatment in rheumatoid arthritis (RA). Although these drugs have contributed to change the…
Abstract Number: 2443 • 2018 ACR/ARHP Annual Meeting
Trends in the Incidence of Lymphomas and Leukemias in Patients with Rheumatoid Arthritis in Spain: An Observational Cohort Study of Hospital Discharges from 1999 to 2015
J.L Morell-Hita¹, Ramon Mazzucchelli², E Perez-Fernandez², Javier Quirós², Cristina Macia-Villa³, Natalia Crespí⁴, M Peña², Carmen Barbadillo⁵, Maria Espinosa⁶, Hilda Godoy⁵, Manuel Fernández⁷, María Galindo⁸, Alberto Garcia-Vadillo⁹, O Guzon-Illescas², Angela Herranz¹⁰, Cristina Martinez-Prada¹¹, C Morado-Quiñoa¹¹ and Virginia Villaverde García¹², ¹H.U.Ramón y Cajal, Madrid, Spain, ²H.U.Fundación Alcorcón, Madrid, Spain, ³Hospital Universitario Severo Ochoa, Madrid, Spain, ⁴C.S. La Rivota, Madrid, Spain, ⁵H.U. Puerta de Hierro, Madrid, Spain, ⁶Rheumatology, H.U. Puerta de Hierro, Madrid, Spain, ⁷Hospital Universitario de Guadalajara. Spain, Guadalajara, Spain, ⁸Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰H.U. del Henares, Madrid, Spain, ¹¹H.U. Clínico San Carlos, Madrid, Spain, ¹²Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain
Background/Purpose: Oncohematological diseases have an increased incidence in Rheumatoid Arthritis (RA) patients. In the last years numerous studies have appeared exploring the relationship between these…
Abstract Number: 2929 • 2016 ACR/ARHP Annual Meeting
The Baseline Th17 Lymphocytes Level Is a Predictive Marker of Good Response to Biologics in Rheumatoid Arthritis
Sarah Salomon¹, Caroline Guignant², Pierre Morel³, Brigitte Gubler⁴, Patrice Fardellone⁵, Jean-Pierre Marolleau⁶ and Vincent Goeb⁷, ¹Rheumatology, University Hospital of Amiens, Amiens, France, ²Immunology Laboratory, University Hospital of Amiens, Amiens, France, ³Hematology, University Hospital of Amiens, Amiens, France, ⁴Immunology, University Hospital of Amiens, Amiens, France, ⁵Department of Rheumatology, Amiens University hospital, Amiens, France, ⁶hematology, University Hospital of Amiens, Amiens, France, ⁷Rheumatology, Amiens University Hospital, Amiens, France
Background/Purpose: In clinical daily practice, the response to biologic drugs is unpredictable in patients with rheumatoid arthritis (RA). Thus, there is a crucial need for…
Abstract Number: 1047 • 2015 ACR/ARHP Annual Meeting
Characterization of Changes in Lymphocyte Subsets in Baricitinib-Treated Patients with Rheumatoid Arthritis in Two Phase 3 Studies
Paul Emery¹, Iain McInnes², Mark C. Genovese³, Josef S. Smolen⁴, Joel Kremer⁵, Maxime Dougados⁶, Douglas E. Schlichting⁷, Terence Rooney⁷, Maher Issa⁷, Stephanie de Bono⁷, William L. Macias⁷, Veronica Rogai⁷, Steven H. Zuckerman⁷ and Peter C. Taylor⁸, ¹Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ²Glasgow Biomedical Research Centre, Glasgow, United Kingdom, ³Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁴Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Albany Medical College, Albany, NY, ⁶Paris-Descartes University, Paris, France, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford Botnar Research Centre, Oxford, United Kingdom
Background/Purpose: Baricitinib (bari) is an oral, reversible inhibitor of Janus kinase (JAK)1/JAK2 being developed as QD treatment for patients (pts) with RA. In phase (ph)…
Abstract Number: 2733 • 2015 ACR/ARHP Annual Meeting
Effect of Abatacept on Telomerase Activity of Lymphocytes of Patients with Rheumatoid Arthritis
Kazuhiro Otani¹, Haruyasu Ito¹, Kenichiro Hirai², Kentaro Noda², Ken Yoshida², Isamu Kingetsu² and Daitaro Kurosaka², ¹Internal Medicine, Jikei University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: Telomere is a component of chromosome, and protects end of chromosome from various stress. Telomere shortens during cell division, and telomerase maintains telomere length.…
Abstract Number: 1745 • 2014 ACR/ARHP Annual Meeting
Memory Stem T Cells Are Selectively Enriched in Patients with Rheumatoid Arthritis, Contract upon Anti-TNF Treatment, and May Provide a Long-Term Reservoir of Arthritogenic Lymphocytes
Nicoletta Cieri¹, Giacomo Oliveira¹, Raffaella Greco², Mattia Baldini³, Elena Baldissera⁴, Fabio Ciceri² and Chiara Bonini¹, ¹Division of Immunology, Infectious Diseases and Transplants, Experimental Hematology Unit, San Raffaele Scientific Institute, Milan, Italy, ²Division of Regenerative Medicine, Gene Therapy and Stem Cells, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy, ³Division of Immunology, Infectious Diseases and Transplants, Clinical immunopathology and advanced medical therapeutics, San Raffaele Scientific Institute, Milan, Italy, ⁴Clinical immunopathology and advanced medical therapeutics, San Raffaele Scientific Institute, Milan, Italy
Background/Purpose: the T-cell memory compartment is multi-faceted and encompasses multiple subsets with divergent properties. In addition to central memory (TCM) and effector memory (TEM) cells,…
Abstract Number: 1516 • 2014 ACR/ARHP Annual Meeting
TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis
Marlene Andersen¹, Michael Kruse Meyer², Ivan Nagaev³, Olga Nagaeva³, Jarl E.S. Wikberg⁴, Lucia Mincheva-Nilsson³ and Grethe N. Andersen², ¹Department of Rheumatology, Aalborg University, Hjørring, Denmark, ²Clinic of Rheumatology, Hospital of Vendsyssel/Aalborg University, Hjørring, Denmark, ³Department of Clinical Immunology, University of Umeå, Umeå, Sweden, ⁴Department of Pharmaceutical Biosciences, Department of Pharmaceutical Pharmacology, Uppsala, Sweden
Background/Purpose: We examined Adalimumab´s effects on melanocortin receptor subtype (MC)1-5 gene expression in important leukocyte subsets in rheumatoid arthritis (RA). The melanocortin system is a…
Abstract Number: 2404 • 2013 ACR/ARHP Annual Meeting
CXCL13-Producing CD4 T-Cells In Rheumatoid Synovitis Are a Distinct Subset
Shio Kobayashi¹, Koichi Murata², Hideyuki Shibuya², Masahiro Ishikawa², Moritoshi Furu³, Hiromu Ito³, Shuichi Matsuda², Takeshi Watanabe⁴ and Hiroyuki Yoshitomi⁵, ¹Center for Innovation in Immunoregulative Technology ant Therapeutics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Center for Innovation in Immunoregulative Technology and Therapeutics, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁵Department of Innovation Center for Immunoregulation Technologies and Drugs, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Ectopic lymphoid structures are frequently formed in synovial tissues of patients with rheumatoid arthritis (RA). Several reports suggested that CD4 T-cells have a crucial…
Abstract Number: 1400 • 2013 ACR/ARHP Annual Meeting
Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease
José M. Pego-Reigosa¹, Oscar Cordero², Tania López-González², Coral Mouriño-Rodríguez³, Bruno Aspe⁴, Juan Viñuela-Roldán⁵, Rubén Varela-Calviño⁶, Cristina Calviño⁶, Marina Rodríguez-López⁴, Íñigo Hernández-Rodríguez⁴ and Víctor del Campo-Pérez⁷, ¹Instituto de Investigación Biomédica de Vigo (IBIV), Vigo, Spain, ²Biochemistry and Molecular Biology, Universidade de Santiago de Compostela, Santiago de Compostela, Spain, ³Rheumatology, Meixoeiro Hospital, Vigo, Spain, ⁴Rheumatology, University Hospital Complex of Vigo, Vigo, Spain, ⁵Immunology, University Hospital Complex of Santiago, Santiago de Compostela, Spain, ⁶Biochemistry and Molecular Biology, Faculty of Pharmacy, University of Santiago de Compostela, Santiago de Compostela, Spain, ⁷Preventive Medicine and Epidemiology, University Hospital Complex of Vigo, Vigo, Spain
Background/Purpose: Dipeptidyl peptidase IV (DPP-IV, CD26), a protease cleaving N-terminal X-Pro dipeptides from selected proteins including chemokines is expressed both as a soluble form and…
Abstract Number: 1385 • 2013 ACR/ARHP Annual Meeting
A Study Of Natural Killer Cell Subfractions In Abatacept Therapy For Rheumatoid Arthritis
Masao Sato¹, Masao Takemura², Ryuki Shinohe¹, Yasuko Yamamoto³ and Kuniaki Saito³, ¹Orthopaedic Surgery, Gifu University, Gifu, Japan, ²Informative Clinical Medicine, Gifu University, Gifu, Japan, ³Human Health Science, Kyoto University, Kyoto, Japan
Background/Purpose: Inflammatory cytokines and cell-mediated immunity function of mainly lymphocytes are complicatedly involved in disease onset of rheumatoid arthritis (RA). Recently, together with biologicals such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].